TABLE OF CONTENTS
|  | | | | Volume 100, Issue 2
Published online 22 January 2009 (221-430)
|  | In this issue
 Minireview
Minireviews
Clinical Studies
Translational Therapeutics
Molecular Diagnostics
Genetics and Genomics
Also new today
 Advance online publication
| | | | | | Advertisement | | British Journal of Cancer publishes high quality original papers and reviews that make a significant contribution to increasing understanding of the causes of cancer and to improving the treatment and survival of patients.
Visit the journal online at www.bjcancer.com to view the latest research and access selected articles FREE of charge. | | | | | | British Journal of Cancer has an impact factor 4.635 * and is ranked 27/132 in Oncology*.
*2007 Journal Citation Report (Thomson Reuters, 2008)
| | | | | Minireview | Top | | Normal stem cells in cancer prone epithelial tissues T J Phesse & A R Clarke Br J Cancer 2009 100: 221-227; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604850 Abstract | Full Text | | Minireviews | Top | | The spliceosome as target for anticancer treatment R J van Alphen, E A C Wiemer, H Burger & F A L M Eskens Br J Cancer 2009 100: 228-232; advance online publication, November 25, 2008; 10.1038/sj.bjc.6604801 Abstract | Full Text | | | | Folate and colorectal cancer prevention R A Hubner & R S Houlston Br J Cancer 2009 100: 233-239; advance online publication, December 16, 2008; 10.1038/sj.bjc.6604823 Abstract | Full Text | | | | Concepts of epigenetics in prostate cancer development C S Cooper & C S Foster Br J Cancer 2009 100: 240-245; advance online publication, November 11, 2008; 10.1038/sj.bjc.6604771 Abstract | Full Text | | Clinical Studies | Top | | Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials J P Neoptolemos, D D Stocken, C Tudur Smith, C Bassi, P Ghaneh, E Owen, M Moore, R Padbury, R Doi, D Smith & M W Büchler Br J Cancer 2009 100: 246-250; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604838 Abstract | Full Text | | | | Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience R A Adams, A M Meade, A Madi, D Fisher, E Kay, S Kenny, R S Kaplan & T S Maughan Br J Cancer 2009 100: 251-258; 10.1038/sj.bjc.6604877 Abstract | Full Text | | | | Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? G Grazzini, C B Visioli, M Zorzi, S Ciatto, F Banovich, A G Bonanomi, A Bortoli, G Castiglione, L Cazzola, M Confortini, P Mantellini, T Rubeca & M Zappa Br J Cancer 2009 100: 259-265; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604864 Abstract | Full Text | | | | Deficient mismatch repair system in patients with sporadic advanced colorectal cancer M Koopman, G A M Kortman, L Mekenkamp, M J L Ligtenberg, N Hoogerbrugge, N F Antonini, C J A Punt & J H J M van Krieken Br J Cancer 2009 100: 266-273; 10.1038/sj.bjc.6604867 Abstract | Full Text | | | | Development and pilot evaluation of a complex intervention to improve experienced continuity of care in patients with cancer M King, L Jones, O McCarthy, M Rogers, A Richardson, R Williams, A Tookman & I Nazareth Br J Cancer 2009 100: 274-280; advance online publication, December 23, 2008; 10.1038/sj.bjc.6604836 Abstract | Full Text | | | | Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan M Kondo, S-L Hoshi & M Toi Br J Cancer 2009 100: 281-290; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604869 Abstract | Full Text | | | | A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer T Neuhaus, Y Ko, R P Muller, G G Grabenbauer, J P Hedde, H Schueller, M Kocher, S Stier & R Fietkau Br J Cancer 2009 100: 291-297; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604835 Abstract | Full Text | | | | Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer S-W Han, D-Y Oh, S-A Im, S R Park, K-W Lee, H S Song, N-S Lee, K H Lee, I S Choi, M H Lee, M A Kim, W H Kim, Y-J Bang & T-Y Kim Br J Cancer 2009 100: 298-304; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604861 Abstract | Full Text | | | | A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer R L Jones, G Walsh, S Ashley, S Chua, R Agarwal, M O'Brien, S Johnston & I E Smith Br J Cancer 2009 100: 305-310; 10.1038/sj.bjc.6604862 Abstract | Full Text | | Translational Therapeutics | Top | | Direct effects of doxorubicin on skeletal muscle contribute to fatigue K van Norren, A van Helvoort, J M Argilés, S van Tuijl, Karin Arts, M Gorselink, A Laviano, D Kegler, H P Haagsman & E M van der Beek Br J Cancer 2009 100: 311-314; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604858 Abstract | Full Text | | | | Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours M Campone, V Levy, E Bourbouloux, D Berton Rigaud, D Bootle, C Dutreix, U Zoellner, N Shand, F Calvo & E Raymond Br J Cancer 2009 100: 315-321; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604851 Abstract | Full Text | | | | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53 S C Naumann, W P Roos, E Jöst, C Belohlavek, V Lennerz, C W Schmidt, M Christmann & B Kaina Br J Cancer 2009 100: 322-333; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604856 Abstract | Full Text | | | | Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin X Wu, A Wanders, P Wardega, B Tinge, L Gedda, S Bergstrom, L Sooman, J Gullbo, M Bergqvist, P Hesselius, J Lennartsson & S Ekman Br J Cancer 2009 100: 334-343; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604855 Abstract | Full Text | | Molecular Diagnostics | Top | | Promoter CpG methylation in cancer cells contributes to the regulation of MUC4 N Yamada, Y Nishida, H Tsutsumida, M Goto, M Higashi, M Nomoto & S Yonezawa Br J Cancer 2009 100: 344-351; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604845 Abstract | Full Text | | | | Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression M Anders, M Vieth, C Röcken, M Ebert, M Pross, S Gretschel, P M Schlag, B Wiedenmann, W Kemmner & M Höcker Br J Cancer 2009 100: 352-359; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604876 Abstract | Full Text | | | | CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients J Harder, V Engelstaedter, H Usadel, S Lassmann, M Werner, P Baier, F Otto, M Varbanova, E Schaeffner, M Olschewski, H E Blum & O G Opitz Br J Cancer 2009 100: 360-365; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604859 Abstract | Full Text | | | | A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 G Descamps, P Gomez-Bougie, C Venot, P Moreau, R Bataille & M Amiot Br J Cancer 2009 100: 366-369; 10.1038/sj.bjc.6604839 Abstract | Full Text | | Genetics and Genomics | Top | | LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition C L Mahoney, B Choudhury, H Davies, S Edkins, C Greenman, G van Haaften, T Mironenko, T Santarius, C Stevens, M R Stratton & P A Futreal Br J Cancer 2009 100: 370-375; 10.1038/sj.bjc.6604886 Abstract | Full Text | | | | The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome M Clyne, J Offman, S Shanley, J D Virgo, M Radulovic, Y Wang, A Ardern-Jones, R Eeles, E Hoffmann & V P C C Yu Br J Cancer 2009 100: 376-380; advance online publication, January 13, 2009; 10.1038/sj.bjc.6604860 Abstract | Full Text | | | | Nuclear oxidative damage correlates with poor survival in colorectal cancer J Sheridan, L-M Wang, M Tosetto, K Sheahan, J Hyland, D Fennelly, D O'Donoghue, H Mulcahy & J O'Sullivan Br J Cancer 2009 100: 381-388; advance online publication, December 9, 2008; 10.1038/sj.bjc.6604821 Abstract | Full Text | | | | Cross talk between hedgehog and epithelial–mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers H Ohta, K Aoyagi, M Fukaya, I Danjoh, A Ohta, N Isohata, N Saeki, H Taniguchi, H Sakamoto, T Shimoda, T Tani, T Yoshida & H Sasaki Br J Cancer 2009 100: 389-398; advance online publication, December 23, 2008; 10.1038/sj.bjc.6604846 Abstract | Full Text | | | | RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker A Misawa, S Tanaka, S Yagyu, K Tsuchiya, T Iehara, T Sugimoto & H Hosoi Br J Cancer 2009 100: 399-404; 10.1038/sj.bjc.6604887 Abstract | Full Text | | | | The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy E Y Tan, M Yan, L Campo, C Han, E Takano, H Turley, I Candiloro, F Pezzella, K C Gatter, E K A Millar, S A O'Toole, C M McNeil, P Crea, D Segara, R L Sutherland, A L Harris & S B Fox Br J Cancer 2009 100: 405-411; 10.1038/sj.bjc.6604844 Abstract | Full Text | | | | Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium C L Pearce, A M Near, D J Van Den Berg, S J Ramus, A Gentry-Maharaj, U Menon, S A Gayther, A R Anderson, C K Edlund, A H Wu, X Chen, J Beesley, P M Webb, S K Holt, C Chen, J A Doherty, M A Rossing, A S Whittemore, V McGuire, R A DiCioccio, M T Goodman, G Lurie, M E Carney, L R Wilkens, R B Ness, K B Moysich, R Edwards, E Jennison, S K Kjaer, E Hogdall, C K Hogdall, E L Goode, T A Sellers, R A Vierkant, J C Cunningham, J M Schildkraut, A Berchuck, P G Moorman, E S Iversen, D W Cramer, K L Terry, A F Vitonis, L Titus-Ernstoff, H Song, P D P Pharoah, A B Spurdle, H Anton-Culver, A Ziogas, W Brewster, V Galitovskiy & G Chenevix-Trench Br J Cancer 2009 100: 412-420; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604820 Abstract | Full Text | | | | Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation K A Metcalfe, A Finch, A Poll, D Horsman, C Kim-Sing, J Scott, R Royer, P Sun & S A Narod Br J Cancer 2009 100: 421-425; advance online publication, December 16, 2008; 10.1038/sj.bjc.6604830 Abstract | Full Text | | | | A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer Z Kote-Jarai, S Jugurnauth, S Mulholland, D A Leongamornlert, M Guy, S Edwards, M Tymrakiewitcz, L O'Brien, A Hall, R Wilkinson, A A Al Olama, J Morrison, K Muir, D Neal, J Donovan, F Hamdy, D F Easton & R Eeles Br J Cancer 2009 100: 426-430; advance online publication, January 6, 2009; 10.1038/sj.bjc.6604847 Abstract | Full Text | | | | | | | Advertisement | | Ensure your access to British Journal of Cancer
If you are unable to access the articles in this Table of Contents e-alert, your library may not subscribe to this journal. Our online recommendation form is a simple way to make your librarian aware that this journal is valuable to your research.
Recommend now at www.nature.com/librec/svc/request/makeCommRequest?id=2. | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2009 Nature Publishing Group |  | | | | |
